[SCHEDULE 13G/A] Korro Bio, Inc. SEC Filing

Rhea-AI Filing Summary

Korro Bio received a Schedule 13G/A disclosing that members of the Point72/Steven A. Cohen group collectively beneficially own 816,905 shares, representing 8.7% of Korro Bio's common stock as of the close of business on June 30, 2025. The filing breaks ownership across affiliated entities: Point72 Asset Management and Point72 Capital Advisors each report shared voting and dispositive power over 540,074 shares (5.8% each at the reporting-person level), while certain Point72 affiliates each report 276,831 shares (2.9%). No reporting person claims sole voting or dispositive power; the filing states the holdings were not acquired to change or influence control.

Positive

• Clear disclosure of aggregate beneficial ownership: 816,905 shares representing 8.7% of the class as of June 30, 2025
• Affiliation and ownership structure across Point72 entities and Steven A. Cohen is explicitly described, improving transparency for investors
• Filing certifies holdings were not acquired to change or influence control, clarifying intent

Negative

• No sole voting or dispositive power reported by any filing entity, indicating limited direct control despite a material stake

Insights

Securities Analyst

TL;DR: Point72/Steven Cohen group disclosed an 8.7% passive stake in Korro Bio with only shared voting/dispositive power.

The Schedule 13G/A confirms a significant minority position by the Point72 group totaling 816,905 shares (8.7%). The structure of holdings is spread across multiple affiliated entities, with shared voting and dispositive power reported and no sole control asserted. The filing includes the required certification that the securities were not acquired to effect control. For investors, this clarifies ownership concentration and governance influence without a claim of control.

Corporate Governance Expert

TL;DR: Disclosure shows material stake but limited asserted control; affiliations and voting arrangements are clearly described.

The report maps beneficial ownership through funds and holding companies to Steven A. Cohen, showing 816,905 shares beneficially owned and detailed shared powers by reporting entities. The absence of sole voting/dispositive power and the certification language indicate a non-control intent under the filer’s statement. The filing improves transparency about potential coordinated shareholder influence while not registering as an active control filing.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)

Korro Bio, Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

500946108

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 500946108

1

Names of Reporting Persons

Point72 Asset Management, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 540,074.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 540,074.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

540,074.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.8 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP No. 500946108

1

Names of Reporting Persons

Point72 Capital Advisors, Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 540,074.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 540,074.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

540,074.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.8 %

12

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13G

CUSIP No. 500946108

1

Names of Reporting Persons

Point72 Biotech Private Investments, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 276,831.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 276,831.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

276,831.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

2.9 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP No. 500946108

1

Names of Reporting Persons

Differentiated Ventures Investments, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 276,831.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 276,831.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

276,831.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

2.9 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP No. 500946108

1

Names of Reporting Persons

72 Investment Holdings, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 276,831.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 276,831.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

276,831.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

2.9 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP No. 500946108

1

Names of Reporting Persons

Steven A. Cohen

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 816,905.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 816,905.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

816,905.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

8.7 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Korro Bio, Inc.
(b)	Address of issuer's principal executive offices: 60 First Street, 2nd Floor, Suite 250, Cambridge, MA 02141.
Item 2.
(a)	Name of person filing: This statement is filed by: (i) Point72 Asset Management, L.P. ("Point72 Asset Management") with respect to the shares of common stock, par value $0.001 per share ("Common Stock") of Korro Bio, Inc. held by Point72 Associates, LLC, an investment fund it manages ("Point72 Associates"); (ii) Point72 Capital Advisors, Inc. ("Point72 Capital Advisors Inc."), the general partner of Point72 Asset Management, with respect to the shares of Common Stock held by Point72 Associates; (iii) Point72 Biotech Private Investments, LLC ("Point72 Biotech") with respect to the shares of Common Stock of which it is the holder; (iv) Differentiated Ventures Investments, LLC ("Differentiated Ventures"), the managing member of Point72 Biotech, with respect to the shares of Common Stock held by Point72 Biotech; (v) 72 Investment Holdings, LLC ("72 Investment Holdings"), the sole member of Differentiated Ventures, with respect to the shares of Common Stock held by Point72 Biotech, and (vi) Steven A. Cohen ("Mr. Cohen"), the sole member of 72 Investment Holdings and sole shareholder of Point72 Capital Advisors Inc., with respect to the shares of Common Stock beneficially owned by Point72 Asset Management, Point72 Capital Advisors Inc., Point72 Biotech, Differentiated Ventures, and 72 Investment Holdings.
(b)	Address or principal business office or, if none, residence: The address of the principal business office of Point72 Asset Management, Point72 Capital Advisors Inc., Point72 Biotech, Differentiated Ventures, 72 Investment Holdings, and Mr. Cohen is 72 Cummings Point Road, Stamford, CT 06902.
(c)	Citizenship: Point72 Asset Management is a Delaware limited partnership. Point72 Capital Advisors Inc. is a Delaware corporation. Point72 Biotech, Differentiated Ventures, and 72 Investment Holdings are Delaware limited liability companies. Mr. Cohen is a United States citizen.
(d)	Title of class of securities: Common Stock, par value $0.001 per share
(e)	CUSIP No.: 500946108
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on June 30, 2025. Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen own directly no shares of Common Stock. Pursuant to an investment management agreement, Point72 Asset Management maintains investment and voting power with respect to the securities held by Point72 Associates. Point72 Capital Advisors Inc. is the general partner of Point72 Asset Management. Pursuant to an investment management agreement, Mr. Cohen controls each of Point72 Asset Management and Point72 Capital Advisors Inc. Differentiated Ventures is the managing member of Point72 Biotech and may be deemed to share beneficial ownership over the shares of Common Stock held by Point72 Biotech. 72 Investment Holdings is the sole member of Differentiated Ventures and may be deemed to share beneficial ownership of the shares of Common Stock of which Differentiated Ventures may be deemed the beneficial owner. The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Securities and Exchange Act of 1934, the beneficial owner of the Common Stock reported herein.
(b)	Percent of class: 8.7%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on June 30, 2025.
	(ii) Shared power to vote or to direct the vote: The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on June 30, 2025.
	(iii) Sole power to dispose or to direct the disposition of: The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on June 30, 2025.
	(iv) Shared power to dispose or to direct the disposition of: The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on June 30, 2025.
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. See Item 2(a). Point72 Associates has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, more than 5 percent of the outstanding shares of Common Stock.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Point72 Asset Management, L.P.

Signature:	/s/ Jason M. Colombo
Name/Title:	Jason M. Colombo, Authorized Person
Date:	08/14/2025

Point72 Capital Advisors, Inc.

Signature:	/s/ Jason M. Colombo
Name/Title:	Jason M. Colombo, Authorized Person
Date:	08/14/2025

Point72 Biotech Private Investments, LLC

Signature:	/s/ Vincent Tortorella
Name/Title:	Vincent Tortorella, Authorized Person
Date:	08/14/2025

Differentiated Ventures Investments, LLC

Signature:	/s/ Vincent Tortorella
Name/Title:	Vincent Tortorella, Authorized Person
Date:	08/14/2025

72 Investment Holdings, LLC

Signature:	/s/ Jason M. Colombo
Name/Title:	Jason M. Colombo, Authorized Person
Date:	08/14/2025

Steven A. Cohen

Signature:	/s/ Jason M. Colombo
Name/Title:	Jason M. Colombo, Authorized Person
Date:	08/14/2025

FAQ

How many Korro Bio (KRRO) shares does the Point72/Steven A. Cohen group beneficially own?

The filing reports an aggregate of 816,905 shares beneficially owned by the group, representing 8.7% of the outstanding common stock as of June 30, 2025.

Does Point72 or Steven A. Cohen claim control of Korro Bio (KRRO)?

No reporting person claims sole voting or sole dispositive power, and the filing includes a certification that the securities were not acquired to change or influence control.

Which Point72 entities are listed as reporting persons on the Schedule 13G/A for KRRO?

Reported filers include Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., Point72 Biotech Private Investments, LLC, Differentiated Ventures Investments, LLC, 72 Investment Holdings, LLC, and Steven A. Cohen.

What portion of the reported stake is held by Point72 Asset Management and Point72 Capital Advisors?

Each of Point72 Asset Management and Point72 Capital Advisors reports shared voting and dispositive power over 540,074 shares, equal to 5.8% of the class at the reporting-person level.

What date is the ownership information in the Schedule 13G/A based on?

The ownership information is stated to be as of the close of business on June 30, 2025.